Undifferentiated high grade pleomorphic sarcoma of bone

disease

On this page

Also known as malignant bone fibrous histiocytomamalignant fibrous histiocytoma of bonemalignant fibrous histiocytoma of the boneundifferentiated high grade pleomorphic sarcomaundifferentiated high-grade pleomorphic sarcoma

Summary

Undifferentiated high grade pleomorphic sarcoma of bone (MONDO:0002618) is a cancer and 5 clinical trials. Top therapeutic interventions include pazopanib, ifosfamide, and lifileucel. A subtype of bone sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

Classification: Cancer
Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	undifferentiated high grade pleomorphic sarcoma of bone
Mondo ID	MONDO:0002618
DOID	DOID:3352
NCIT	C8563
UMLS	C0740479
MedGen	149264
GARD	0023190
Is cancer (heuristic)	yes

Also known as: malignant bone fibrous histiocytoma · malignant fibrous histiocytoma of bone · malignant fibrous histiocytoma of the bone · undifferentiated high grade pleomorphic sarcoma · undifferentiated high grade pleomorphic sarcoma of bone · undifferentiated high-grade pleomorphic sarcoma

Disease family

This is a subtype of bone sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › bone cancer › bone sarcoma › undifferentiated high grade pleomorphic sarcoma of bone

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
PHASE2/PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02180867	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
NCT03449108	PHASE2	ACTIVE_NOT_RECRUITING	LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT00667342	PHASE2	COMPLETED	A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma
NCT04420975	PHASE1	ACTIVE_NOT_RECRUITING	Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
NCT01674101	Not specified	COMPLETED	Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PAZOPANIB	4	3
IFOSFAMIDE	4	2
LIFILEUCEL	4	1
CHEMBL4068768	0	1
CHEMBL4171277	0	1

Drugs: Pazopanib, Ifosfamide, Lifileucel